Kolexia
Rad-Quesnel Emilia
Oncologie médicale
Centre Hospitalier de Roubaix
Roubaix, France
50 Activités
11 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du pancréas Déficit en dihydropyrimidine déshydrogénase Adénocarcinome Tumeurs colorectales {{person.topmesh6.name}} {{person.topmesh7.name}} {{person.topmesh8.name}} {{person.topmesh9.name}} {{person.topmesh10.name}}

Industries

A+A
66 collaboration(s)
Dernière en 2023
IQVIA
54 collaboration(s)
Dernière en 2023
Inter-View Partners France
6 collaboration(s)
Dernière en 2023
EXAFIELD
3 collaboration(s)
Dernière en 2023

Dernières activités

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma.
Therapeutic advances in medical oncology   16 juillet 2021
Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.
2021 ASCO Annual Meeting I   28 mai 2021
1531P FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC)
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
A randomized cross-over trial comparing single-agents capecitabine (C) and UFT plus leucovorin (LV) in patients (Pts) with advanced colorectal cancer (CRC): Preliminary data of a patient preference study.
2011 Gastrointestinal Cancers Symposium   01 février 2011
{{person.lastact5.name}}
{{person.lastact5.jour}}   {{person.lastact5.date}}
{{person.lastact6.name}}
{{person.lastact6.jour}}   {{person.lastact6.date}}
{{person.lastact7.name}}
{{person.lastact7.jour}}   {{person.lastact7.date}}
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}